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Supplementary methods 17 
 18 
Analyses of thyroid function tests and biochemical parameters 19 
Serum total T3 concentrations were measured by Vitros ECI technology (Ortho‐Clinical Diagnostics, 20 
Beerse, Belgium) until April 12 2019 and afterwards by Lumipulse G1200 (Fujirebio Inc., Ghent, 21 
Belgium), and by Immulite 2000 XPi (Siemens Healthcare, The Hague, The Netherlands). Free T4, total 22 
T4 and TSH concentrations were measured by Vitros ECI technology (Ortho‐Clinical Diagnostics, 23 
Beerse, Belgium) until April 12 2019 and afterwards by Lumpulse G1200 (Fujirebio Inc., Ghent, 24 
Belgium). Sex hormone-binding globulin (SHBG) was measured using an immunometric method 25 
(Immulite 2000 XPi (Siemens Healthcare, The Hague, The Netherlands)). Creatine kinase (CK) and 26 
creatinine were measured by Cobas 8000 (Roche Diagnostics, Almere, The Netherlands).  27 
To account for any interference of Triac in the measurement of serum T3 concentrations, we used an 28 
algorithm based on the different levels of cross-reactivity of Triac in two T3 assays, as reported before 29 
(1). To minimize the interference of Triac in the T3 assays, parents were instructed to have blood 30 
samples collected in the morning before the administration of the morning Triac dose. This procedure 31 
ensured a minimum washout time of ~8 hours. With a half-life time of 6.5 hours, Triac concentrations 32 
in the blood were expected at their lowest levels (2, 3).  33 
In case of suspected endogenous antibody interference in the T3 Vitros assay at baseline measurement 34 
(defined as a difference with other assays of more than 5 nmol/L) (4), T3 Lumipulse or T3 35 
radioimmunoassay (RIA) measurement was used for analyses. 36 
Analyses of anthropometric parameters and heart rate 37 
Body weight- and height-for-age and weight-for-height Z scores were calculated using the TNO growth 38 
calculator (5) and heart rate-for-age Z scores were calculated using the Boston Z score calculator (6). 39 
Weight-for-age and height-for-age Z scores were compared to the available natural history data 40 
obtained in a cohort of Triac-naïve patients (7). The difference to the natural history curve was 41 
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determined for each subject at indicated time-points and used for comparison. Using this strategy, the 42 
deterioration of these parameters in untreated patients was fully considered. Given the scarcity of 43 
natural history data in subjects aged above 18 years, subjects older than 18 years at baseline were 44 
excluded from analyses. Tanner stages of sexual maturation were determined by each patient’s 45 
physician. 46 
In addition to statistical analyses, changes in body weight- and height-for-age compared to the natural 47 
history reference line and heart rate-for-age were descriptively analyzed. Increase of body weight- and 48 
height-for-age compared to the natural history reference line and heart rate-for-age was defined as a 49 
change from baseline to last visit of >0.25 SDs. Stabilization of body weight- and height-for-age 50 
compared to the natural history reference line and heart rate-for-age was defined as a change from 51 
baseline to last visit of 0.25 to -0.25 SDs.  Decrease of body weight- and height-for-age compared to 52 
the natural history reference line and heart rate-for-age was defined as a change from baseline to last 53 
visit of <-0.25 SDs. These cut-off values were chosen as they were deemed clinically relevant by the 54 
lead investigators (FSvG, SG, WEV). Changes in Tanner stages of sexual maturation were descriptively 55 
analyzed. 56 
Safety 57 
The data capture monitoring system included the following pre-defined adverse events during follow-58 
up: 59 
- Diarrhea 60 
- Vomiting 61 
- Sweating 62 
- Shortness of breath 63 
- Skin rash 64 
- Anxiety 65 
- Other 66 
Other safety end points were embedded in the clinical outcomes such as heart rate and body weight. 67 
In addition, the occurrence of hospital admission and its relationship with Triac treatment were 68 
monitored during follow-up. 69 
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Figure S1: Study design 70 
 71 
Figure S1: Outline of the study. Grey dashed boxes indicate the cohorts selected for analyses. All 72 
patients who concluded Triac Trial I were offered to continue Triac treatment on off-label use basis 73 
when possible. Continuation of treatment on off-label use basis was not possible in all countries mostly 74 
due to regulatory difficulties (applicable for five patients). During the Triac Trial I, newly identified 75 
Page 5 of 18 
 
families who pursued Triac treatment were informed about the existence of Triac Trial I. However, for 76 
12 patients participation was not possible due to the absence of a hub center in their country and 28 77 
patients were identified after the recruitment phase. 78 
  79 
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Figure S2: Distribution of treated patients around the world 80 
81 
Figure S2: Light yellow indicates <0.1 treated patients per 10 million residents; yellow indicates 0.1 – 82 
0.5 treated patients per 10 million residents; light orange indicates 0.5 – 1 treated patients per 10 83 
million residents; orange indicates 1 – 2 treated patients per 10 million residents; red indicates 2 – 5 84 
treated patients per 10 million residents; dark red indicates > 5 treated patients per 10 million 85 
residents (8, 9). 86 
  87 
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Figure S3: Cohort characteristics 88 
 89 
Figure S3: Characteristics of the combined cohort, divided into patients originally enrolled in Triac Trial 90 
I (Triac Trial I) and patients who were directly treated on off-label use basis (Off-label use). (A) Age 91 
distribution of treated patients; (B) Treatment exposure of patients, shown in years.   92 
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Figure S4: Timing of measurement of outcomes 93 
 94 
Figure S4: Timing of baseline, interim and last available measurement of outcomes for each patient. 95 
(A) Thyroid function tests; (B) Anthropometric outcomes and heart rate; (C) Peripheral markers of 96 
thyroid hormone action. Individual points indicate the timing of outcome measurement at baseline, 97 
after one year of treatment and at the last visit (or last available). Blue bars represent the treatment 98 
period of each patient (based on the last serum control in the central lab, except for patients followed 99 
in the Erasmus Medical Center); dashed light blue bars indicate continuation of treatment up to 100 
January 1th 2021 (81% of patients). In 9 patients, the last available measurements of the different 101 
anthropometric outcomes and heart rate were captured at different moments. *Longitudinal within-102 
subject analyses were performed in patients who were treated >2 years. †Patient deceased. 103 
Abbreviations: JAN=January.   104 
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Figure S5: Change from baseline to last visit in height-for-age 105 
 106 
Figure S5: Panel A shows changes in body height-for-age between baseline and last visit (blue dots and 107 
lines; n=43); the natural history of untreated patients with MCT8 deficiency is depicted in grey dots 108 
with the historical reference line in red (with the 95% error band in dashed lines), based on a historical 109 
control group (7). Panel B shows the change in difference between the body height-for-age Z-score 110 
and the expected Z-score based on the natural history data on the corresponding age from baseline to 111 
one year and last available visit (longitudinal within-subject analyses; n=23). Panel C shows changes in 112 
body height-for-age between baseline and last visit (dots and lines; n=16) of patients who were in 113 
pubertal age (8-18 years) during treatment; green lines indicate patients in pre-pubertal state, light 114 
blue lines indicate patients in puberty. The natural history of untreated patients with MCT8 deficiency 115 
is depicted in grey dots with the historical reference line in red (with the 95% error band in dashed 116 
lines), based on a historical control group (7). Median treatment duration was  2.2 years (IQR 1.5 – 3.9 117 
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years) for analyses of secondary outcomes (panel A) and 3.6 years (IQR 2.5 – 5.2 years) for longitudinal 118 
within-subject analyses (panel B). Body height-for-age Z scores were calculated using TNO growth 119 
calculator. 120 
  121 
Page 11 of 18 
 
Figure S6: Change from baseline to last visit in serum TSH, free T4 and T4 concentrations 122 
123 
Figure S6: Panel A shows changes in serum concentrations of TSH between baseline and last available 124 
follow-up visit on treatment with Triac (n=61). Panel B shows the change in serum TSH concentrations 125 
from baseline to one year and last available visit (longitudinal within-subject analyses; n=34; for clarity, 126 
data are depicted as non-transformed in panels A and B). Panel C shows changes in serum 127 
concentrations of free T4 between baseline and last available follow-up visit on treatment with Triac 128 
(n=63). Panel D shows the change in serum free T4 concentrations from baseline to one year and last 129 
available visit (longitudinal within-subject analyses; n=36). Panel E shows changes in serum 130 
concentrations of T4 between baseline and last available control visit on treatment with Triac (n=62). 131 
Panel F shows the change in serum T4 concentrations from baseline to one year and last available visit 132 
(longitudinal within-subject analyses; n=36). Median treatment duration was 2.2 years (IQR 1.5 – 3.9 133 
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years) for analyses of secondary outcomes (panels A, C and E)  and 3.6 years (IQR 2.5 – 5.2 years) for 134 
longitudinal within-subject analyses (panels B, D and F). Black dashed lines represent the reference 135 
intervals (for the median baseline age). Red dots represent baseline measurement and blue arrows 136 
represent the last available measurement in panels A, C and E. Grey dots represent measurements in 137 
the individual patients in panels B, D and F; means and SEM are displayed in blue. Results of analyses 138 
after stratification based on treatment duration are provided in supplementary table 1. Abbreviations: 139 
TSH=thyroid-stimulating hormone. T4=thyroxine. 140 
  141 
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Figure S7: Change from baseline to last visit in Tanner stage in patients between 8 and 18 years 142 
during treatment 143 
 144 
Figure S7: Changes in Tanner stage on treatment with Triac in patients between 8 and 18 years during 145 
treatment. Each graph represents an individual patient (n=17; complete information not available for 146 
7 patients). Blue dots represent individual measurement. Grey bars represent the normal ranges 147 
(based on (10), with normal ranges determined as median ± 2SD). 148 
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Table S1: Mean changes from baseline to last visit in primary and secondary outcomes after 149 
stratification based on treatment duration 150 
Treatment duration 
(years) 
< 1  
n=7 
≥ 1 – 3  
n=34 
≥ 3 – 5   
n=10 
≥ 5  
n=12 
P value 
Primary outcome      
T3 (nmol/L) -2.68 (1.01) -3.11 (1.46) -3.19 (0.73) -2.38 (1.20) 0.2715 
      
Secondary outcomes      
Anthropometric parameters 
and heart rate 
     
Body weight (kg) 3.08 (2.87) 3.79 (2.74) 6.56 (7.78) 11.15 (6.47)  
Weight-for-age Z score  0.55 (1.73) 0.28 (1.21) -0.33 (1.46) 0.14 (1.40) 0.5717 
Δ Weight-for-age – predicted 
weight-for-age Z score  
0.85 (1.65) 0.76 (1.11) 0.36 (1.49) 0.88 (1.89) 0.8464 
Height (cm) 8 (6) 10 (7) 22 (14) 28 (9)  
Height-for-age Z score  0.21 (0.47) -0.30 (1.42) 0.38 (1.51) -0.14 (0.97) 0.6006 
Δ Height-for-age – predicted 
height-for-age Z score  
0.47 (0.47) 0.18 (1.35) 1.44 (2.05) 1.03 (0.90) 0.1506 
Heart rate (bpm) -2 (24) -13 (24) -29 (21) -24 (21) 0.1274 
Heart rate-for-age Z score  0.00 (1.27) -0.42 (1.13) -1.31 (1.05) -1.01 (1.24) 0.0991  
     
Thyroid function tests      
TSH (mU/L)* -2.15 (1.51) -2.90 (2.79) -1.69 (1.69) -1.69 (1.69) 0.0981 
Free T4 (pmol/L) -5.9 (2.1) -6.7 (2.3) -6.6 (2.5) -3.9 (1.8) 0.0055 
T4 (nmol/L) -40 (18) -36 (13) -41 (14) -30 (11) 0.2325  
     
Peripheral markers      
Sex hormone-binding globulin 
(nmol/L) 
-1 (61) -48 (69) -10 (88) -39 (58) 0.3788 
Creatinine (µmol/L) 8 (1) 5 (5) 10 (5) 10 (5) 0.0403 
Creatine kinase (U/L)* 56 (36) 33 (86) 4 (29) -13 (129) 0.5551  
     
All outcomes were assessed in all patients who received Triac treatment longer than the mean time to optimal 
dose (5.0 months). Data are represented as mean (SD). Abbreviations: T3=tri-iodothyronine. TSH=thyroid-
stimulating hormone. T4=thyroxine. *TSH and creatine kinase concentrations were log-transformed to ensure a 
normal distribution before one-way ANOVAs were done (non-transformed means [SDs] are presented for the 
sake of interpretability). 
 151 
  152 
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Table S2: Mean changes from baseline to one year and last visit in primary and secondary outcomes (longitudinal within-subject analyses) 153 
 Baseline 
mean (SD)  
One year mean 
(SD) 
Mean change from 
baseline (95% CI) 
Last visit mean 
(SD) 
Mean change from 
baseline (95% CI) 
P value * 
Primary outcome       
T3 (nmol/L; n=36) 4.60 (0.99) 1.80 (0.62) -2.81 (-3.27 to -2.34) 1.70 (0.60) -2.90 (-3.37 to -2.44) <0.0001 
       
Secondary outcomes       
Anthropometric parameters and heart rate       
Body weight (kg; n=34) 19.4 (12.5) 21.8 (12.1) 2.4 (0.2 to 4.6) 27.1 (15.1) 7.7 (5.6 to 9.9)  
Weight-for-age Z score (n=34) -3.10 (1.96) -2.91 (1.86) 0.18 (-0.32 to 0.68) -2.91 (1.85) 0.19 (-0.31 to 0.69) 0.4579 
Δ Weight-for-age – predicted weight-for-age Z 
score (n=32) 
0.03 (1.92) 0.44 (1.92) 0.42 (-0.13 to 0.96) 0.88 (2.02) 0.86 (0.31 to 1.40) 0.0039 
Height (cm; n=24) 108 (21) 116 (21) 8 (3 to 13) 127 (20) 19 (14 to 25) 
 
Height-for-age Z score (n=24) -2.11 (1.79) -1.92 (1.41) 0.19 (-0.34 to 0.78) -2.13 (1.75) -0.03 (-0.61 to 0.56) 0.9335 
Δ Height-for-age – predicted height-for-age Z 
score (n=23) 
-0.45 (1.37) 0.04 (1.21) 0.48 (-0.18 to 1.14) 1.44 (1.56) 0.89 (0.23 to 1.55) 0.0178 
Heart rate (bpm; n=19) 114 (25) 103 (17) -11 (-24 to 1) 95 (17) -20 (33 to 7) 0.0036 
Heart rate-for-age Z score (n=19)  1.74 (1.08) 1.36 (0.81) -0.38 (-1.01 to 0.25) 1.03 (0.77) -0.70 (-1.33 to -0.09) 0.0271  
      
Thyroid function tests       
TSH (mU/L; n=34)† 2.99 (1.79) 1.18 (1.39) -1.82 (-2.53 to -1.11) 1.08 (0.74) -1.91 (-2.62 to -1.20) <0.0001 
Free T4 (pmol/L; n=36) 9.6 (2.6) 3.8 (2.1) -5.9 (-6.9 to -4.8) 3.8 (1.6) -5.8 (-6.9 to -4.8) <0.0001 
T4 (nmol/L; n=36) 54 (10) 25 (11) -29 (-34 to -23) 20 (10) -33 (-39 to -28) <0.0001  
      
Peripheral markers       
Sex hormone-binding globulin (nmol/L; n=22) 229 (91) 188 (72) -40 (-74 to -7) 187 (78) -41 (-75 to -7) 0.0084 
Creatinine (µmol/L; n=19) 35 (11) 40 (15) 6 (2 to 9) 43 (14) 8 (4 to 12) <0.0001 
Creatine kinase (U/L; n=19)† 125 (121) 211 (279) 86 (-29 to 201) 135 (84) 10 (-105 to 125) 0.2579  
      
All outcomes were assessed in all patients who received Triac treatment longer than the mean time to optimal dose (5.0 months). Data are mean. Abbreviations: T3=tri-iodothyronine. 
TSH=thyroid-stimulating hormone. T4=thyroxine. *Paired T-tests were used to detect significant changes from baseline to last visit. †TSH and creatine kinase concentrations were 
log-transformed to ensure a normal distribution before one way ANOVAs were done (non-transformed means [SDs] are presented for the sake of interpretability). 
 154 
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Mean change (95% 
CI) 
P value 
Anthropometric parameters and 
heart rate 
    
Body weight (kg; n=62) 17.2 (12.0) 22.6 (14.5) 5.4 (4.0 to 6.8) 
 
Weight-for-age Z score (n=62) -2.84 (1.94) -2.67 (1.79) 0.17 (-0.17 to 0.50) 0.3230 
Δ Weight-for-age – predicted 
weight-for-age Z score (n=59) 
-0.03 (1.84) 0.66 (1.92) 0.70 (0.35 to 1.05) 0.0002 
Height (cm; n=46) 100 (21) 115 (23) 15 (11 to 18)  
Height-for-age Z score (n=46) -1.82 (1.76) -1.90 (1.51) -0.09 (-0.48 to 0.31) 0.6615 
Δ Height-for-age – predicted 
height-for-age Z score (n=45) 
-0.45 (1.37) 0.11 (1.40) 0.56 (0.12 to 1.00) 0.0135 
Weight-for-height Z score (n=46) -2.09 (2.51) -1.58 (2.43) 0.51 (-0.33 to 1.34) 0.2272 
Heart rate (bpm; n=52) 114 (20) 98 (19) -16 (-22 to -9) <0.0001 
Heart rate-for-age Z score (n=52) 1.56 (0.87) 0.96 (0.98) -0.60 (- 0.92 to -0.27) 0.0005 
Thyroid function tests 
    
TSH (mU/L; n=65)* 3.47 (2.37) 1.04 (0.96) -2.43 (-2.99 to -1.86) <0.0001 
Free T4 (pmol/L; n=67) 9.6 (2.3) 3.5 (1.7) -6.0 (-6.6 to -5.5) <0.0001 
T4 (nmol/L; n=66) 54.6 (11.9) 18.7 (10.3) -35.8 (-39.2 to -32.5) <0.0001  
    
Peripheral markers 
    
Sex hormone-binding globulin 
(nmol/L; n=48) 
247 (100) 212 (93) -35 (-55 to -15) 0.0011 
Creatinine (µmol/L; n=46) 32 (11) 39 (13) 7 (6 to 9) <0.0001 
Creatine kinase (U/L; n=46)* 110 (87) 128 (80) 18 (-8 to 45) 0.2166 
 
    
All outcomes were assessed in all patients who received Triac treatment longer than the mean time to 
optimal dose (5.0 months). Data are mean. TSH=thyroid-stimulating hormone. T4=thyroxine. *TSH and 
creatine kinase concentrations were log-transformed to ensure a normal distribution before paired t tests 
were done (non-transformed means [SDs] and mean changes [95% Cis] are presented for the sake of 
interpretability). 
 156 
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Table S4: Overview of Adverse Events deemed related to Triac treatment as judged by the investigators 158 









#1 Increased irritability 6.0 Transient 525 Yes, decreased Resolved without sequelae 
#2 Increased anxiety 13.7 Transient 1050 No Resolved without sequelae 
#3 Increased anxiety and 
sadness 
6.3 Transient 700 No Resolved without sequelae 
#4 Increased irritability 
and reduced sleep 
1.2 Transient, after dose increase 350 Yes, decreased Resolved without sequelae 
#5* Increased sweating 
and irritability, 
tachycardia 
15.9 Transient 700 No Returned later during treatment (irritability), 
otherwise resolved without sequelae 
#6* Increased irritability 
and anxiety 
15.9 Transient 1400 No Returned later during treatment (anxiety), 
otherwise resolved without sequelae 
#7* Increased blood 
pressure, tachycardia 
and increased anxiety 
15.9 Transient, after dose increase 
(for increased blood pressure 
and tachycardia) 
1700 Yes, decreased Resolved without sequelae 
*These events occurred in the same patient. 
 159 
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